Please use this identifier to cite or link to this item: https://doi.org/10.1155/2017/2740372
Title: Continuous Glucose Monitoring in Newly Diagnosed Type 2 Diabetes Patients Reveals a Potential Risk of Hypoglycemia in Older Men
Authors: Li, F.-F
Liu, B.-L
Zhu, H.-H
Li, T
Zhang, W.-L
Su, X.-F
Wu, J.-D
Wang, X.-Q
Xu, N
Yu, W.-N
Yuan, Q
Qi, G.-C
Ye, L 
Lee, K.-O 
Ma, J.-H
Keywords: glucose
human insulin
metformin
antidiabetic agent
glucose blood level
insulin
adult
Article
blood glucose monitoring
China
clinical feature
clinical trial (topic)
continuous glucose monitoring
continuous infusion
diabetic patient
drug dose increase
drug dose reduction
drug dose titration
female
glucose blood level
glucose sensor
human
hypoglycemia
insulin infusion
major clinical study
male
middle aged
non insulin dependent diabetes mellitus
retrospective study
aged
analysis
blood
chemically induced
Diabetes Mellitus, Type 2
drug administration
insulin infusion
risk factor
subcutaneous drug administration
Adult
Aged
Blood Glucose
Diabetes Mellitus, Type 2
Drug Administration Schedule
Female
Humans
Hypoglycemia
Hypoglycemic Agents
Infusions, Subcutaneous
Insulin
Insulin Infusion Systems
Male
Middle Aged
Retrospective Studies
Risk Factors
Issue Date: 2017
Publisher: Hindawi
Citation: Li, F.-F, Liu, B.-L, Zhu, H.-H, Li, T, Zhang, W.-L, Su, X.-F, Wu, J.-D, Wang, X.-Q, Xu, N, Yu, W.-N, Yuan, Q, Qi, G.-C, Ye, L, Lee, K.-O, Ma, J.-H (2017). Continuous Glucose Monitoring in Newly Diagnosed Type 2 Diabetes Patients Reveals a Potential Risk of Hypoglycemia in Older Men. Journal of Diabetes Research 2017 : 2740372. ScholarBank@NUS Repository. https://doi.org/10.1155/2017/2740372
Rights: Attribution 4.0 International
Abstract: Objectives. We performed continuous glucose monitoring (CGM) to define the features of patients with newly diagnosed type 2 diabetes (T2D) before and after Continuous Subcutaneous Insulin Infusion (CSII) therapy. Methods. This was a retrospective analysis. Newly diagnosed T2D patients (106) were admitted from eight centers in China. They were divided into a younger patient group (<60 years) and an older patient group (?60 years). Each group was further divided into male and female patients. CSII therapy was maintained for 3 weeks after the glycemic target was reached. CGM was performed 2 times before and after completion of insulin treatment. Results. CGM data showed the expected significant improvement of mean amplitude glycemic excursion (MAGE) with CSII therapy. The older patients had lower hourly glucose concentrations from 0200 to 0700 o'clock compared to the younger patients at baseline. Surprisingly, in the older patient group, the male patients had a potential risk of hypoglycemia after CSII therapy, especially during periods from 2300 to 2400 and 0400 to 0600. Conclusions. Our data suggested that older male patients with newly diagnosed T2D may have lower nocturnal glucose concentrations. This may potentially increase the risk of nocturnal hypoglycemia during CSII therapy. This study was registered with Chinese Clinical Trial Registry, number CliCTR-TRC-11001218. © 2017 Feng-fei Li et al.
Source Title: Journal of Diabetes Research
URI: https://scholarbank.nus.edu.sg/handle/10635/183580
ISSN: 2314-6745
DOI: 10.1155/2017/2740372
Rights: Attribution 4.0 International
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1155_2017_2740372.pdf1.5 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

10
checked on Jan 12, 2021

Page view(s)

64
checked on Jan 14, 2021

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons